Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan

Yuan Hung Wu, Yu Mei Kang, Yu Wen Hu, Keng Li Lan, Sang Hue Yen, Tzu Yu Lai, Tien Li Lan, Yuh Min Chen, Chao Hua Chiu, Yung Hung Luo, Heng sheng Chao, Chi Lu Chiang, Tsu Hui Shiao, Chao Neng Yang, Wen Hu Hsu, Yu Chung Wu, Han Shui Hsu, Jung Jyh Hung, Chien Sheng Huang, Po Kuei HsuYi Wei Chen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early-stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population. Methods: To evaluate the effects of old age and EGFR mutation on treatment outcomes and toxicity, we reviewed the medical records of 71 consecutive patients with inoperable early-stage non-small cell lung cancer (NSCLC) who received SABR at Taipei Veterans General Hospital between 2015 and 2021. Results: The study revealed that median age, follow-up, Charlson comorbidity index, and ECOG score were 80 years, 2.48 years, 3, and 1, respectively. Of these patients, 37 (52.1%) were 80 years or older, and 50 (70.4%) and 21 (29.6%) had T1 and T2 diseases, respectively. EGFR mutation status was available for 33 (46.5%) patients, of whom 16 (51.5%) had a mutation. The overall survival rates at 1, 3, and 5 years were 97.2, 74.9, and 58.3%, respectively. The local control rate at 1, 3, and 5 years was 97.1, 92.5, and 92.5%, respectively. Using Cox proportional hazards regression we found that male sex was a risk factor for overall survival (p = 0.036, 95% CI: 1.118–26.188). Two patients had grade 2 pneumonitis, but no other grade 2 or higher toxicity was observed. We did not find any significant differences in treatment outcomes or toxicity between patients aged 80 or older and those with EGFR mutations in this cohort. Conclusion: These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early-stage NSCLC.

Original languageEnglish
JournalThoracic Cancer
DOIs
StateAccepted/In press - 2023

Keywords

  • EGFR
  • lung cancer
  • old age
  • SABR

Fingerprint

Dive into the research topics of 'Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan'. Together they form a unique fingerprint.

Cite this